4.8 Article

Structures of the HER2-HER3-NRG1β complex reveal a dynamic dimer interface

Journal

NATURE
Volume 600, Issue 7888, Pages 339-+

Publisher

NATURE PORTFOLIO
DOI: 10.1038/s41586-021-04084-z

Keywords

-

Funding

  1. UCSF Program for Breakthrough Biomedical Research
  2. NIH/NIGMS [R35-GM118099, R35-GM139636]
  3. Genentech research grant
  4. NIH/NCI [1F30CA247147, U54-CA209891]
  5. DFG German Research Foundation [GZ: TR 1668/1-1]

Ask authors/readers for more resources

This study reveals the dynamics of the HER2-HER3 dimer upon binding of NRG1 beta using cryo-electron microscopy. The analysis of the structure shows that the mutant HER2 can interact with the dimerization arm of HER3 to stabilize the dimerization interface. The research suggests that both therapeutic agents and oncogenic mutations exploit the intrinsic dynamics of the HER2-HER3 heterodimer.
Human epidermal growth factor receptor 2 (HER2) and HER3 form a potent pro-oncogenic heterocomplex(1-3) upon binding of growth factor neuregulin-1 beta (NRG1 beta). The mechanism by which HER2 and HER3 interact remains unknown in the absence of any structures of the complex. Here we isolated the NRG1 beta-bound near full-length HER2-HER3 dimer and, using cryo-electron microscopy, reconstructed the extracellulardomain module, revealing unexpected dynamics at the HER2-HER3 dimerization interface. We show that the dimerization arm of NRG1 beta-bound HER3 is unresolved because the apo HER2 monomer does not undergo a ligand-induced conformational change needed to establish a HER3 dimerization arm-binding pocket. In a structure of the oncogenic extracellular domain mutant HER2(S310F), we observe a compensatory interaction with the HER3 dimerization arm that stabilizes the dimerization interface. Both HER2-HER3 and HER2(S310F)-HER3 retain the capacity to bind to the HER2-directed therapeutic antibody trastuzumab, but the mutant complex does not bind to pertuzumab. Our structure of the HER2(S310F)-HER3-NRG1 beta-trastuzumab Fab complex reveals that the receptor dimer undergoes a conformational change to accommodate trastuzumab. Thus, similar to oncogenic mutations, therapeutic agents exploit the intrinsic dynamics of the HER2-HER3 heterodimer. The unique features of a singly liganded HER2-HER3 heterodimer underscore the allosteric sensing of ligand occupancy by the dimerization interface and explain why extracellular domains of HER2 do not homo-associate via a canonical active dimer interface.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available